|
cardiabase currently supplies more than 30 international pharmaceutical companies, device manufacturers and biotechnology companies.
It is anticipated that over 100 projects will be conducted in 2009, including 12 thorough QT studies.
The proportion of repeat business of cardiabase is significant (between 80% and 90% of the annual volume) while the number of new sponsors keeps on growing.
cardiabase supports a growing number of Phase III multinational trials, thanks to significant efforts spent on setting up the necessary logistics and site support services.
|
|
More specifically, cardiabase has been selected as the preferred provider for Phase I ECG services by 5 of the top 10 pharmaceutical companies.
cardiabase is also the preferred partner of several specialist providers (Central Laboratories, Contract Research Organisations, Academic Centres, Phase I Clinics...).
|
